Skip to main content

A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.

Publication: Sci Rep (2016) • Vol 6 • Page 22338PMID: 26936516View on PubMed

Purpose

This paper compared genotyping results by next-generation sequencing (NGS) with those by conventional methods in formalin-fixed paraffin embedded (FFPE) lung adenocarcinoma specimens.

Conclusion

NGS detected all mutations identified by conventional methods as well as some additional ones including therapeutically-actionable mutations in some specimens.

Studies (1)

Purpose

This study compared genotyping results by next-generation sequencing with those by conventional methods in 119 FFPE lung adenocarcinoma specimens. After xylene deparaffinization, DNA was extracted using the QIAamp DNA FFPE tissue kit. A panel of 145 genes was sequenced using an Ion Proton Sequencer. The results were compared with those obtained previously using amplification refractory mutation system (ARMS)-PCR, fluorescent in situ hybridization (FISH), or Sanger Sequencing.

Summary of Findings

NGS detected all mutations identified by ARMS-PCR, FISH, or Sanger Sequencing in 61 specimens, including those in specimens containing only 10-15% tumor cells. However, additional mutations were identified by NGS in some specimens that were not identified by ARMS-PCR or FISH. Further, using an additional 58 specimens, NGS identified 1.4 times as many actionable mutations as ARMS-PCR or FISH.

  • Biospecimens

    TissueLung
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNANext generation sequencing
    DNADNA sequencing
    DNAFISH
    DNAPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Next generation sequencing SpecificTechnology platform
    ARMS-PCR
    FISH
    Sanger sequencing